Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine save search
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Published: 2024-01-08 (Crawled : 17:00) - globenewswire.com
NIPNF | $68.91 -52.94% 120
|
Technology Services
| Email alert
Add to watchlist
tg4050 vaccine cancer collaboration
HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China
Published: 2024-01-08 (Crawled : 12:00) - globenewswire.com
HLVX | $12.29 3.63% 3.5% 280K
|
|
| O: 0.72%
H: 2.22%
C: 0.33%
candidate vaccine license norovirus agreement china
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Published: 2024-01-05 (Crawled : 13:30) - biospace.com/
CVAC | $2.44 0.0% 790K
|
Health Technology
|
| O: 0.71%
H: 4.24%
C: 2.12%
covid-19 vaccine positive collaboration program technology platform
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
Published: 2024-01-04 (Crawled : 21:00) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -1.72%
H: 1.77%
C: -1.05%
PPRUY | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: -1.13%
H: 1.81%
C: 0.95%
PCVX | $60.82 0.33% 0.33% 1.3M
|
Health Technology
|
| O: -2.53%
H: 0.56%
C: -4.66%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: -4.28%
H: 0.0%
C: -17.88%
pneumococcal vaccine update potential
Fluzone High-Dose Quadrivalent vaccine remains preferentially recommended to protect adults 65 years of age and older against influenza
Published: 2024-01-03 (Crawled : 22:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.49%
H: 0.0%
C: -0.26%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.38%
H: 0.0%
C: 0.0%
vaccine influenza
GeoVax Announces Issuance of Malaria Vaccine Patent
Published: 2024-01-03 (Crawled : 14:00) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 2.7%
H: 5.26%
C: -1.5%
patent vaccine malaria
Vaxart Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers
Published: 2023-12-21 (Crawled : 13:00) - globenewswire.com
VXRT | News | $0.7652 -9.15% -10.08% 1.9M
|
Health Technology
|
| O: 1.16%
H: 1.64%
C: -1.64%
candidate vaccine norovirus trial
BioNTech Achieves Milestone at mRNA-based Vaccine Manufacturing Site in Rwanda
Published: 2023-12-18 (Crawled : 18:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: 0.0%
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
|
| O: 0.9%
H: 2.47%
C: 2.11%
vaccine milestone
Provectus Biopharmaceuticals Announces Notice of Allowance of First U.S. Patent of Rose Bengal Sodium for Use as Anticancer and Antiviral Vaccine Adjuvant
Published: 2023-12-18 (Crawled : 13:00) - globenewswire.com
PVCT 4 | $0.195 -15.0% 56K
|
Manufacturing
|
| O: 0.0%
H: 0.73%
C: -15.5%
first patent rose antiviral vaccine
Influenza Vaccine Market to grow by USD 2.93 billion from 2022 to 2027; North America to account for 54% of market growth - Technavio
Published: 2023-12-13 (Crawled : 19:00) - prnewswire.com
CMXHF | $172.54 -19.21% 50
|
n/a
|
| O: 5.56%
H: 0.71%
C: 0.71%
CSLLY | $86.918 3.3% 60K
|
n/a
|
| O: 1.46%
H: 3.01%
C: 0.97%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.58%
H: 0.0%
C: -1.01%
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 1.19%
H: 3.09%
C: 1.3%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: 0.76%
H: 1.0%
C: -0.11%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: 1.7%
H: 2.44%
C: 1.78%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.21%
H: 0.27%
C: -0.52%
america vaccine influenza growth market
AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
Published: 2023-12-12 (Crawled : 15:30) - biospace.com/
AZNCF | News | $138.24 -4.19% 800
|
Health Technology
|
| O: 5.03%
H: 0.0%
C: -3.82%
ICVX | $15.31 -0.65% 9.3M
|
|
| O: 53.48%
H: 1.02%
C: 0.26%
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.54%
H: 0.06%
C: -0.78%
vaccine astrazeneca positive acquire rsv potential
Icosavax Announces Positive Topline Interim Phase 2 Results for Combination VLP Vaccine Candidate IVX-A12 Against RSV and hMPV in Older Adults
Published: 2023-12-12 (Crawled : 07:00) - globenewswire.com
ICVX | $15.31 -0.65% 9.3M
|
|
| O: 53.48%
H: 1.02%
C: 0.26%
candidate vaccine positive topline rsv results
AstriVax Awarded €3 Million Grant to Advance therapeutic Hepatitis B Vaccine
Published: 2023-12-12 (Crawled : 07:00) - biospace.com/
BNPQY | $34.61 -2.68% 100K
|
Finance and Insurance
|
| O: -0.3%
H: 0.12%
C: 0.03%
hepatitis vaccine grant
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
Published: 2023-12-06 (Crawled : 23:00) - prnewswire.com
ANIX | $3.12 0.65% 0.64% 33K
|
Health Technology
|
| O: 2.29%
H: 5.63%
C: -10.45%
vaccine breast positive cancer study
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
Published: 2023-12-06 (Crawled : 21:00) - prnewswire.com
ANIX | $3.12 0.65% 0.64% 33K
|
Health Technology
|
| O: 2.29%
H: 5.63%
C: -10.45%
conference vaccine breast positive cancer ongoing study
Novavax's Updated COVID-19 Vaccine Now Authorized in Canada
Published: 2023-12-05 (Crawled : 21:00) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 0.18%
H: 3.93%
C: -0.36%
covid-19 authorized vaccine canada
VAX-24 Phase 1/2 Adult Proof-of-Concept Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 24-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Published: 2023-12-04 (Crawled : 00:00) - globenewswire.com
PCVX | $60.82 0.33% 0.33% 1.3M
|
Health Technology
|
| O: -0.15%
H: 1.65%
C: -0.72%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: -0.7%
H: 1.05%
C: -0.35%
vax-24 candidate pneumococcal vaccine lancet potential
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15
Published: 2023-12-04 (Crawled : 21:00) - globenewswire.com
PFE A | $26.0 2.4% -0.15% 38M
|
Health Technology
|
| O: -0.24%
H: 1.34%
C: -0.41%
vla15 disease vaccine valneva trial
GSK Pulls Ahead of Pfizer in RSV Vaccine Market as Arexvy Nears Blockbuster S...
Published: 2023-12-01 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: -0.05%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
vaccine rsv market
GSK Pulls Ahead of Pfizer in RSV Vaccine Market as Arexvy Nears Blockbuster Status
Published: 2023-12-01 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 1.39%
H: 0.0%
C: -0.05%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.93%
H: 0.0%
C: 0.0%
vaccine rsv market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.